FIREBRICK PHARMA LIMITED - Announcements

1.32%

7.5¢

Market Cap $17.04M

Healthcare Biotechnology

Firebrick Pharma (ASX:FRE) is an Australian pharmaceutical developer focused on... Firebrick Pharma (ASX:FRE) is an Australian pharmaceutical developer focused on developing and commercializing novel formulations and uses of povidone-iodine. After more than 10 years of R&D including multiple human clinical trials, Firebrick's first product, Nasodine® Nasal Spray, is now available for sale in USA and Singapore.More

Corporate Spotlight

Firebrick Pharma (ASX:FRE) is an Australian pharmaceutical developer focused on developing and commercializing novel formulations and uses of povidone-iodine. After more than 10 years of R&D including multiple human clinical trials, Firebrick's first product, Nasodine® Nasal Spray, is now available
View the full Corporate Spotlight

FIREBRICK PHARMA - JUNE INVESTOR WEBINAR

Announcements

Filter Results

All Price Sensitive Only

FRE	Cleansing Notice		19/12/23	138.53KB	Share
FRE	Application for quotation of securities - FRE		19/12/23	24.83KB	Share
FRE	Nasodine COVID-19 Patent Granted in South Africa		29/11/23	147.5KB	Share
FRE	Results of Annual General Meeting		17/11/23	159.91KB	Share
FRE	Firebrick Investor Update	PRICE SENSITIVE	15/11/23	176.44KB	Share
FRE	Firebrick Receives $1.81m R&D Tax Incentive	PRICE SENSITIVE	31/10/23	146.31KB	Share
FRE	September 2023 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	27/10/23	229.96KB	Share
FRE	Letter to Shareholders & Notice of AGM & Proxy Form		17/10/23	592.97KB	Share
FRE	Update on Nasodine Trial and Forward Plans	PRICE SENSITIVE	03/10/23	163.23KB	Share
FRE	Notice of AGM and Closing Date for Director Nominations		18/09/23	137.76KB	Share
FRE	Phase 3 Common Cold Trial Results	PRICE SENSITIVE	13/09/23	185.34KB	Share
FRE	Trading Halt	PRICE SENSITIVE	11/09/23	614.24KB	Share
FRE	Appendix 4G		29/08/23	268.62KB	Share
FRE	Corporate Governance Statement		29/08/23	324.39KB	Share
FRE	Appendix 4E & Annual Report FY23	PRICE SENSITIVE	29/08/23	1.93MB	Share
FRE	Response to ASX Price and Volume Query	PRICE SENSITIVE	28/08/23	793.97KB	Share
FRE	Firebrick Phase 3 Trial Closes with 500 Subjects	PRICE SENSITIVE	09/08/23	109.26KB	Share
FRE	Firebrick Covid-19 Trial Achieves Primary Endpoint	PRICE SENSITIVE	07/08/23	151.09KB	Share
FRE	Update on Nasodine Phase 2 Study		01/08/23	133.1KB	Share
FRE	June 2023 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	27/07/23	236.73KB	Share
FRE	Firebrick Update on AAT Process		20/07/23	135.76KB	Share
FRE	Firebrick Update on Phase 2 Trial Results		12/07/23	135.6KB	Share
FRE	Firebrick Update on AAT Schedule		29/06/23	133.71KB	Share
FRE	Cleansing Notice		21/06/23	181.27KB	Share
FRE	Change of Director's Interest Notice - Stephen Goodall		21/06/23	271.95KB	Share
FRE	Change of Director's Interest Notice - Peter Molloy		21/06/23	270.96KB	Share
FRE	Application for quotation of securities - FRE		21/06/23	24.66KB	Share
FRE	Results of General Meeting		20/06/23	157.96KB	Share
FRE	Firebrick Pharma Investor Update on Key Projects		20/06/23	149.64KB	Share
FRE	Notification of cessation of securities - FRE		16/06/23	21.64KB	Share
FRE	Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment	PRICE SENSITIVE	31/05/23	160.77KB	Share
FRE	Update on Nasodine AAT Appeal Timetable		29/05/23	137.87KB	Share
FRE	Letter to Shareholders & Notice of GM & Proxy Form		15/05/23	788.09KB	Share
FRE	Cleansing Notice		09/05/23	111KB	Share
FRE	Application for quotation of securities - FRE		09/05/23	24.58KB	Share
FRE	Nasodine Patent Allowed in Canada		09/05/23	165.76KB	Share
FRE	Proposed issue of securities - FRE		01/05/23	24.88KB	Share
FRE	Proposed issue of securities - FRE		01/05/23	24.56KB	Share
FRE	Firebrick Raises $1 million via Placement	PRICE SENSITIVE	01/05/23	151.07KB	Share
FRE	March 2023 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	20/04/23	258.05KB	Share
FRE	Nasodine COVID-19 Trial Concludes Recruitment	PRICE SENSITIVE	03/04/23	325.78KB	Share
FRE	Cleansing Notice		28/03/23	139.4KB	Share
FRE	Application for quotation of securities - FRE		28/03/23	24.95KB	Share
FRE	Firebrick Pharma's Phase 3 Trial of Nasodine Resumes	PRICE SENSITIVE	21/03/23	379.02KB	Share
FRE	FRE files EU Paediatric Investigation Plan for Nasodine	PRICE SENSITIVE	21/02/23	148.88KB	Share
FRE	Appendix 4D & Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/23	6.77MB	Share
FRE	Investor Presentation - Euroz Hartleys Healthcare Forum		01/02/23	2.03MB	Share
FRE	December 2022 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	19/01/23	366.28KB	Share
FRE	Nasodine Research Points to Potential Role in CRS		18/01/23	196.01KB	Share
FRE	Nasodine Appeal Timetable Agreed at AAT Conference		01/12/22	134KB	Share
FRE	Change of Director's Interest Notice - Phyllis Gardner		24/11/22	274.05KB	Share
FRE	Change of Director's Interest Notice - Richard Treagus		24/11/22	267.27KB	Share
FRE	Notification regarding unquoted securities - FRE		24/11/22	23.64KB	Share
FRE	Notification regarding unquoted securities - FRE		24/11/22	23.64KB	Share
FRE	Constitution		24/11/22	450.52KB	Share
FRE	Results of Annual General Meeting		23/11/22	145.8KB	Share
FRE	Annual General Meeting Presentation		23/11/22	1.15MB	Share
FRE	Firebrick CFO and Accounting Change		14/11/22	124.72KB	Share
FRE	Nasodine Composition Patent Accepted in Australia	PRICE SENSITIVE	14/11/22	154.31KB	Share
FRE	Firebrick Receives $1.08m R&D Tax Incentive	PRICE SENSITIVE	09/11/22	138.29KB	Share
FRE	Proposed issue of securities - FRE		01/11/22	27.95KB	Share
FRE	Firebrick Update on Nasodine Phase 3 Trial		31/10/22	173.4KB	Share
FRE	September 2022 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	31/10/22	352.35KB	Share
FRE	Nasodine Patent Granted in Singapore		25/10/22	159.18KB	Share
FRE	Annual Report to Shareholders		21/10/22	7.44MB	Share
FRE	Letter to Shareholders & Notice of AGM & Proxy Form		21/10/22	972.63KB	Share
FRE	Notification of cessation of securities - FRE		10/10/22	21.65KB	Share
FRE	Notice of AGM and Closing Date for Director Nominations		28/09/22	116.09KB	Share
FRE	Firebrick announces formation of Scientific Advisory Board		14/09/22	135.65KB	Share
FRE	Corporate Governance Statement		23/08/22	322.48KB	Share
FRE	Appendix 4G		23/08/22	267.42KB	Share
FRE	Appendix 4E & Annual Report	PRICE SENSITIVE	23/08/22	7.72MB	Share
FRE	Cleansing Notice		03/08/22	118.73KB	Share
FRE	Application for quotation of securities - FRE		03/08/22	24.82KB	Share
FRE	June 2022 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	29/07/22	343.93KB	Share
FRE	Firebrick Presents at Euroz Hartleys Healthcare Conference		26/07/22	1.45MB	Share
FRE	Outcome of s60 appeal for Nasodine and next steps	PRICE SENSITIVE	07/07/22	137.21KB	Share
FRE	Trading Halt	PRICE SENSITIVE	07/07/22	615.26KB	Share
FRE	Notification of cessation of securities - FRE		22/06/22	21.65KB	Share
FRE	Initial Director's Interest Notice - Richard Treagus		01/06/22	231.97KB	Share
FRE	Proposed issue of securities - FRE		25/05/22	27.95KB	Share
FRE	Nasodine Patent Granted in Malaysia		25/05/22	160.05KB	Share
FRE	Firebrick Appoints Dr Richard Treagus as Director		25/05/22	141.58KB	Share
FRE	Firebrick starts Phase 3 common cold trial of Nasodine	PRICE SENSITIVE	03/05/22	157.28KB	Share
FRE	March 2022 Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	26/04/22	370.37KB	Share
FRE	Firebrick starts COVID-19 trial of Nasodine	PRICE SENSITIVE	26/04/22	167.62KB	Share
FRE	Investor Presentation - Euroz Hartleys Rottnest Conference		11/03/22	1.67MB	Share
FRE	Investor Presentation - Euroz Hartleys Rottnest Conference		11/03/22	1.57MB	Share
FRE	FRE to file appeal seeking immediate approval of Nasodine		01/03/22	135.45KB	Share
FRE	Nasodine US Patent Granted for COVID-19		17/02/22	152.58KB	Share
FRE	31 December Interim Financial Report & Appendix 4D	PRICE SENSITIVE	11/02/22	466.51KB	Share
FRE	Nasodine in vitro and pilot human COVID-19 studies published		10/02/22	150.05KB	Share
FRE	Nasodine COVID-19 trial receives SAHPRA approval		01/02/22	147.36KB	Share
FRE	Becoming a substantial holder - Stephen Goodall		25/01/22	336.69KB	Share
FRE	Becoming a substantial holder - Peter Molloy		25/01/22	368.98KB	Share
FRE	Becoming a substantial holder - Firebrick Pharma		25/01/22	555.04KB	Share
FRE	Initial Director's Interest Notice - Stephen Goodall		25/01/22	242.09KB	Share
FRE	Initial Director's Interest Notice - Peter Molloy		25/01/22	242.27KB	Share
FRE	Initial Director's Interest Notice - Phyllis Gardner		25/01/22	241.28KB	Share
FRE	Pre-Quotation Disclosure		25/01/22	482.9KB	Share

FRE Cleansing Notice
19/12/23		138.53KB	Share
FRE Application for quotation of securities - FRE
19/12/23		24.83KB	Share
FRE Nasodine COVID-19 Patent Granted in South Africa
29/11/23		147.5KB	Share
FRE Results of Annual General Meeting
17/11/23		159.91KB	Share
FRE Firebrick Investor Update
15/11/23	PRICE SENSITIVE	176.44KB	Share
FRE Firebrick Receives $1.81m R&D Tax Incentive
31/10/23	PRICE SENSITIVE	146.31KB	Share
FRE September 2023 Quarterly Activity Report & Appendix 4C
27/10/23	PRICE SENSITIVE	229.96KB	Share
FRE Letter to Shareholders & Notice of AGM & Proxy Form
17/10/23		592.97KB	Share
FRE Update on Nasodine Trial and Forward Plans
03/10/23	PRICE SENSITIVE	163.23KB	Share
FRE Notice of AGM and Closing Date for Director Nominations
18/09/23		137.76KB	Share
FRE Phase 3 Common Cold Trial Results
13/09/23	PRICE SENSITIVE	185.34KB	Share
FRE Trading Halt
11/09/23	PRICE SENSITIVE	614.24KB	Share
FRE Appendix 4G
29/08/23		268.62KB	Share
FRE Corporate Governance Statement
29/08/23		324.39KB	Share
FRE Appendix 4E & Annual Report FY23
29/08/23	PRICE SENSITIVE	1.93MB	Share
FRE Response to ASX Price and Volume Query
28/08/23	PRICE SENSITIVE	793.97KB	Share
FRE Firebrick Phase 3 Trial Closes with 500 Subjects
09/08/23	PRICE SENSITIVE	109.26KB	Share
FRE Firebrick Covid-19 Trial Achieves Primary Endpoint
07/08/23	PRICE SENSITIVE	151.09KB	Share
FRE Update on Nasodine Phase 2 Study
01/08/23		133.1KB	Share
FRE June 2023 Quarterly Activity Report & Appendix 4C
27/07/23	PRICE SENSITIVE	236.73KB	Share
FRE Firebrick Update on AAT Process
20/07/23		135.76KB	Share
FRE Firebrick Update on Phase 2 Trial Results
12/07/23		135.6KB	Share
FRE Firebrick Update on AAT Schedule
29/06/23		133.71KB	Share
FRE Cleansing Notice
21/06/23		181.27KB	Share
FRE Change of Director's Interest Notice - Stephen Goodall
21/06/23		271.95KB	Share
FRE Change of Director's Interest Notice - Peter Molloy
21/06/23		270.96KB	Share
FRE Application for quotation of securities - FRE
21/06/23		24.66KB	Share
FRE Results of General Meeting
20/06/23		157.96KB	Share
FRE Firebrick Pharma Investor Update on Key Projects
20/06/23		149.64KB	Share
FRE Notification of cessation of securities - FRE
16/06/23		21.64KB	Share
FRE Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
31/05/23	PRICE SENSITIVE	160.77KB	Share
FRE Update on Nasodine AAT Appeal Timetable
29/05/23		137.87KB	Share
FRE Letter to Shareholders & Notice of GM & Proxy Form
15/05/23		788.09KB	Share
FRE Cleansing Notice
09/05/23		111KB	Share
FRE Application for quotation of securities - FRE
09/05/23		24.58KB	Share
FRE Nasodine Patent Allowed in Canada
09/05/23		165.76KB	Share
FRE Proposed issue of securities - FRE
01/05/23		24.88KB	Share
FRE Proposed issue of securities - FRE
01/05/23		24.56KB	Share
FRE Firebrick Raises $1 million via Placement
01/05/23	PRICE SENSITIVE	151.07KB	Share
FRE March 2023 Quarterly Activity Report & Appendix 4C
20/04/23	PRICE SENSITIVE	258.05KB	Share
FRE Nasodine COVID-19 Trial Concludes Recruitment
03/04/23	PRICE SENSITIVE	325.78KB	Share
FRE Cleansing Notice
28/03/23		139.4KB	Share
FRE Application for quotation of securities - FRE
28/03/23		24.95KB	Share
FRE Firebrick Pharma's Phase 3 Trial of Nasodine Resumes
21/03/23	PRICE SENSITIVE	379.02KB	Share
FRE FRE files EU Paediatric Investigation Plan for Nasodine
21/02/23	PRICE SENSITIVE	148.88KB	Share
FRE Appendix 4D & Half Yearly Report and Accounts
17/02/23	PRICE SENSITIVE	6.77MB	Share
FRE Investor Presentation - Euroz Hartleys Healthcare Forum
01/02/23		2.03MB	Share
FRE December 2022 Quarterly Activity Report & Appendix 4C
19/01/23	PRICE SENSITIVE	366.28KB	Share
FRE Nasodine Research Points to Potential Role in CRS
18/01/23		196.01KB	Share
FRE Nasodine Appeal Timetable Agreed at AAT Conference
01/12/22		134KB	Share
FRE Change of Director's Interest Notice - Phyllis Gardner
24/11/22		274.05KB	Share
FRE Change of Director's Interest Notice - Richard Treagus
24/11/22		267.27KB	Share
FRE Notification regarding unquoted securities - FRE
24/11/22		23.64KB	Share
FRE Notification regarding unquoted securities - FRE
24/11/22		23.64KB	Share
FRE Constitution
24/11/22		450.52KB	Share
FRE Results of Annual General Meeting
23/11/22		145.8KB	Share
FRE Annual General Meeting Presentation
23/11/22		1.15MB	Share
FRE Firebrick CFO and Accounting Change
14/11/22		124.72KB	Share
FRE Nasodine Composition Patent Accepted in Australia
14/11/22	PRICE SENSITIVE	154.31KB	Share
FRE Firebrick Receives $1.08m R&D Tax Incentive
09/11/22	PRICE SENSITIVE	138.29KB	Share
FRE Proposed issue of securities - FRE
01/11/22		27.95KB	Share
FRE Firebrick Update on Nasodine Phase 3 Trial
31/10/22		173.4KB	Share
FRE September 2022 Quarterly Activity Report & Appendix 4C
31/10/22	PRICE SENSITIVE	352.35KB	Share
FRE Nasodine Patent Granted in Singapore
25/10/22		159.18KB	Share
FRE Annual Report to Shareholders
21/10/22		7.44MB	Share
FRE Letter to Shareholders & Notice of AGM & Proxy Form
21/10/22		972.63KB	Share
FRE Notification of cessation of securities - FRE
10/10/22		21.65KB	Share
FRE Notice of AGM and Closing Date for Director Nominations
28/09/22		116.09KB	Share
FRE Firebrick announces formation of Scientific Advisory Board
14/09/22		135.65KB	Share
FRE Corporate Governance Statement
23/08/22		322.48KB	Share
FRE Appendix 4G
23/08/22		267.42KB	Share
FRE Appendix 4E & Annual Report
23/08/22	PRICE SENSITIVE	7.72MB	Share
FRE Cleansing Notice
03/08/22		118.73KB	Share
FRE Application for quotation of securities - FRE
03/08/22		24.82KB	Share
FRE June 2022 Quarterly Activity Report & Appendix 4C
29/07/22	PRICE SENSITIVE	343.93KB	Share
FRE Firebrick Presents at Euroz Hartleys Healthcare Conference
26/07/22		1.45MB	Share
FRE Outcome of s60 appeal for Nasodine and next steps
07/07/22	PRICE SENSITIVE	137.21KB	Share
FRE Trading Halt
07/07/22	PRICE SENSITIVE	615.26KB	Share
FRE Notification of cessation of securities - FRE
22/06/22		21.65KB	Share
FRE Initial Director's Interest Notice - Richard Treagus
01/06/22		231.97KB	Share
FRE Proposed issue of securities - FRE
25/05/22		27.95KB	Share
FRE Nasodine Patent Granted in Malaysia
25/05/22		160.05KB	Share
FRE Firebrick Appoints Dr Richard Treagus as Director
25/05/22		141.58KB	Share
FRE Firebrick starts Phase 3 common cold trial of Nasodine
03/05/22	PRICE SENSITIVE	157.28KB	Share
FRE March 2022 Quarterly Activity Report & Appendix 4C
26/04/22	PRICE SENSITIVE	370.37KB	Share
FRE Firebrick starts COVID-19 trial of Nasodine
26/04/22	PRICE SENSITIVE	167.62KB	Share
FRE Investor Presentation - Euroz Hartleys Rottnest Conference
11/03/22		1.67MB	Share
FRE Investor Presentation - Euroz Hartleys Rottnest Conference
11/03/22		1.57MB	Share
FRE FRE to file appeal seeking immediate approval of Nasodine
01/03/22		135.45KB	Share
FRE Nasodine US Patent Granted for COVID-19
17/02/22		152.58KB	Share
FRE 31 December Interim Financial Report & Appendix 4D
11/02/22	PRICE SENSITIVE	466.51KB	Share
FRE Nasodine in vitro and pilot human COVID-19 studies published
10/02/22		150.05KB	Share
FRE Nasodine COVID-19 trial receives SAHPRA approval
01/02/22		147.36KB	Share
FRE Becoming a substantial holder - Stephen Goodall
25/01/22		336.69KB	Share
FRE Becoming a substantial holder - Peter Molloy
25/01/22		368.98KB	Share
FRE Becoming a substantial holder - Firebrick Pharma
25/01/22		555.04KB	Share
FRE Initial Director's Interest Notice - Stephen Goodall
25/01/22		242.09KB	Share
FRE Initial Director's Interest Notice - Peter Molloy
25/01/22		242.27KB	Share
FRE Initial Director's Interest Notice - Phyllis Gardner
25/01/22		241.28KB	Share
FRE Pre-Quotation Disclosure
25/01/22		482.9KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 7.5¢		Change -0.001(1.32%)		Mkt cap ! $17.04M

Open	High	Low	Value	Volume
7.5¢	7.5¢	7.5¢	$4.167K	55.55K

Buyers (Bids)

No.	Vol.	Price($)
2	28139	7.6¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	23060	2

View Market Depth

No.	Vol.	Price($)
2	28139	0.076
3	191543	0.075
1	13847	0.072
1	100000	0.071
2	78928	0.070

Price($)	Vol.	No.
0.080	17877	1
0.081	4000	1
0.082	14795	1
0.083	120000	1
0.085	55999	2

Last trade - 09.59am 11/08/2025 (20 minute delay)


Last 7.6¢		Change -0.001 ( 0.00 %)
Open	High	Low	Volume
7.6¢	7.6¢	7.6¢	10000
Last updated 11.15am 11/08/2025 ?

FRE (ASX) Chart

FIREBRICK PHARMA LIMITED - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories